Why CEL-SCI Corporation’s (CVM) Stock Is Down 5.11%
As of Friday, January 30, CEL-SCI Corporation’s CVM share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company’s LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Commentary & Analysis
Why CEL-SCI Corporation’s (CVM) Stock Is Down 5.56%
As of Thursday, January 29, CEL-SCI Corporation’s CVM share price has dipped by 5.56%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why CEL-SCI Corporation’s (CVM) Stock Is Up 8.09%
As of Tuesday, January 27, CEL-SCI Corporation’s CVM share price has surged by 8.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why CEL-SCI Corporation’s (CVM) Stock Is Down 5.62%
As of Friday, January 23, CEL-SCI Corporation’s CVM share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Why CEL-SCI Corporation’s (CVM) Stock Is Down 6.26%
As of Monday, December 01, CEL-SCI Corporation’s CVM share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | CVM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $26.4 | $241.2 | 12% |
|
| Shares Out (Mil) | 12.1 | 53.4 | 23% |
|
| Institutional Ownership | 79.4% | 92.9% | 48% |
|
| Float (Mil) | 16.9 | 41.2 | 26% |
|
| Beta | 0.56 | 0.96 | 32% |
|
| Avg Daily Volume (000s) | 111 | 486 | 38% |
|
| Price Change (52-week) |
(82.6%) | 48.4% | 8% |
|
| Growth | CVM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | 3.5% | (10.1%) | 45% |
|
| EPS (5yr) | 24.0% | 15.8% | 74 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (23.3%) | (15.7%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CVM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($23) | ($44) | 23% |
|
| EPS (TTM) | ($2.569) | ($1.600) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($33) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 25% |
|
| Enterprise Value (Q1) (Mil) | $26 | $177 | 13% |
|
| Valuation | CVM | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.42 | 2.25 | 60% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CVM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (108.9%) | (47.3%) | 5% |
|
| ROE | (252.5%) | (53.3%) | 3% |
|
| Liabilities to Assets | 48.7% | 29.7% | 41% |
|
| F-Score | 4 | 2 | 34% |
|
CEL-SCI Corporation did not pass any screens on 10/29/2026.
